Healthcare / BiotechnologyASX
$0.07
+0.00 (+4.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-5.2M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$49M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-588.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-16.6M · FCF $-14.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | $2.8M | $3.4M | $2.1M |
| Net Income | $-16.6M | $-16.6M | $-7.7M | $-6.2M | $-1.7M | — |
| EBITDA | $-18.5M | $-18.5M | $-6.7M | $-5.8M | $-1.3M | — |
| EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 | — |
| Gross Margin | — | — | — | 72.1% | 90.7% | 89.5% |
| Operating Margin | — | — | — | -131.0% | -81.3% | — |
| Net Margin | — | — | — | -220.0% | -50.5% | — |
| Balance Sheet | ||||||
| Debt/Equity | — | — | — | 0.27 | 0.18 | — |
| Current Ratio | 2.18 | 2.18 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-14.3M | $-14.3M | $-5.2M | $-1.6M | $-1.4M | — |
| Returns | ||||||
| ROE | -588.3% | -588.3% | -75.0% | -159.7% | -21.8% | — |
| Valuation | ||||||
| P/B | 11.42 | 11.42 | 7.37 | 6.72 | 3.66 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | -16.5% | 58.0% | — |
| EPS Growth | -64.3% | -64.3% | -7.3% | -257.4% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.03
Residual
-56.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.